Search

Displaying results 3801 - 3810 of 10000 in total
  1. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … The impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation.

  2. Drug

    Fluocortolone pivalate

    go.drugbank.com/drugs/DB15777
    Investigational

    Mixtures: ULTRALAN CRINALE SOLUSYON, 20 ML, Doloproct 1 mg + 40 mg Zäpfchen
  3. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity (NCT04487210). … Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine.

  4. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

    Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: Drugs Used in Diabetes
  5. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701] … GS030-DP is an optogenetic gene therapy being investigated for the treatment of retinitis pigmentosa.

  6. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.

  7. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

  8. Drug

    Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11002
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Medical Provider Single Use EZ Flu Shot 2018-2019, Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016
  9. Drug

    Methyclothiazide

    go.drugbank.com/drugs/DB00232
    ApprovedWithdrawn

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

    Products: Duretic 5mg
  10. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.